174 related articles for article (PubMed ID: 10469284)
1. A dose-finding study of zoledronate in hypercalcemic cancer patients.
Body JJ; Lortholary A; Romieu G; Vigneron AM; Ford J
J Bone Miner Res; 1999 Sep; 14(9):1557-61. PubMed ID: 10469284
[TBL] [Abstract][Full Text] [Related]
2. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
3. Clinical research update: zoledronate.
Body JJ
Cancer; 1997 Oct; 80(8 Suppl):1699-701. PubMed ID: 9362440
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
6. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
7. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.
Body JJ; Magritte A; Seraj F; Sculier JP; Borkowski A
J Bone Miner Res; 1989 Dec; 4(6):923-8. PubMed ID: 2692407
[TBL] [Abstract][Full Text] [Related]
8. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Morris MJ; Smaletz O; Solit D; Kelly WK; Slovin S; Flombaum C; Curley T; Delacruz A; Schwartz L; Fleisher M; Zhu A; Diani M; Fallon M; Scher HI
Cancer; 2004 May; 100(9):1868-75. PubMed ID: 15112267
[TBL] [Abstract][Full Text] [Related]
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
10. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.
Mitsiades CS; Bogdanos J; Karamanolakis D; Milathianakis C; Dimopoulos T; Koutsilieris M
Anticancer Res; 2006; 26(5B):3693-700. PubMed ID: 17094387
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
[TBL] [Abstract][Full Text] [Related]
13. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and metastatic breast carcinoma.
Lipton A
Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
[TBL] [Abstract][Full Text] [Related]
17. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Callon KE; Gamble GD; Reid IR
J Bone Miner Res; 2008 Aug; 23(8):1304-8. PubMed ID: 18627266
[TBL] [Abstract][Full Text] [Related]
18. Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Body JJ; Dumon JC; Piccart M; Ford J
J Bone Miner Res; 1995 Aug; 10(8):1191-6. PubMed ID: 8585422
[TBL] [Abstract][Full Text] [Related]
19. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
